
TMO Stock Forecast & Price Target
TMO Analyst Ratings
Bulls say
Thermo Fisher Scientific is projected to experience steady revenue growth in its laboratory products and services segment, with an anticipated compound annual growth rate of 5.4% over the next three years. The company is poised to gain market share in the Contract Research Organization (CRO) space, benefiting from increasing trends in biopharma clinical trial outsourcing for both early-stage and late-stage drug development, as indicated by survey responses. Additionally, while analytical instruments revenue is expected to grow at a compound annual rate of 2.5%, this growth comes after a significantly higher growth rate of 6.2% from 2019 to 2024, reflecting a solid foundation for future stability and performance.
Bears say
From 2021 to 2024, Thermo Fisher Scientific experienced a significant decline in adjusted EBIT margin, dropping by approximately 830 basis points to 22.6%, largely due to a 940-basis-point reduction in adjusted gross margin. The company's adjusted gross margin decreased to 42.2%, which is about 420 basis points lower than the 46.4% gross margin recorded in 2019. This deterioration in margins raises concerns about the firm's profitability trends and overall financial health moving forward.
This aggregate rating is based on analysts' research of Thermo Fisher Scientific and is not a guaranteed prediction by Public.com or investment advice.
TMO Analyst Forecast & Price Prediction
Start investing in TMO
Order type
Buy in
Order amount
Est. shares
0 shares